Stalled at the FDA, Amicus adds a preclinical rare disease drug in back-ended $90M deal
Amicus Therapeutics $FOLD has snagged a preclinical drug in a small biotech buyout, beefing up its slim pipeline at a time that the company is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
